Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06544265 · ClinicalTrials.gov registry record · Phase 1
SynKIR-310 for Relapsed/Refractory B-NHL
A Phase 1 study of Mantle Cell Lymphoma and Follicular Lymphoma, sponsored by Verismo Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 5
- Study locations
NCT06544265: Recruiting Phase 1 study of Mantle Cell Lymphoma and Follicular Lymphoma, sponsored by Verismo Therapeutics.
NCT06544265 is a Phase 1 study of Mantle Cell Lymphoma and Follicular Lymphoma that is actively recruiting participants, run by Verismo Therapeutics. The registered enrollment target is 18 participants, below the 104-participant average among 102 other Mantle Cell Lymphoma trials with a reported enrollment target (83% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06544265, a Phase 1 study of Mantle Cell Lymphoma and Follicular Lymphoma, is actively recruiting participants, sponsored by Verismo Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 5
- Study locations
Study Summary
This first-in-human (FIH) trial is designed to assess the safety, feasibility and preliminary efficacy of a single intravenous (IV) dose of SynKIR-310 administered to participants with relapsed/refractory B-NHL.
Primary Outcome
The incidence, frequency, and severity of adverse events (AEs), including serious adverse events (SAEs), treatment-emergent adverse events (TEAEs), and dose-limiting toxicities (DLTs). Presence of RCL-VSV-G
Conditions Studied
Interventions
- BIOLOGICAL SynKIR-310
Study Locations (5)
Colorado
- Colorado Blood Cancer Institute, part of Sarah Cannon Cancer Institute - Denver
Georgia
- Winship Cancer Institute of Emory University - Atlanta
Kansas
- The University of Kansas Cancer Center - Fairway
New Jersey
- Rutgers Cancer Institute - New Brunswick
Pennsylvania
- Abramson Cancer Center of the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2024-11-01 |
| Est. Completion | 2028-12 |
| Phase | Phase 1 |
What NCT06544265 shows while recruiting
NCT06544265 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 104-participant average among 102 other Mantle Cell Lymphoma trials with a reported enrollment target (83% lower).
The record links to 10 conditions, with Mantle Cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which SynKIR-310 is the first listed.
NCT06544265 lists 5 locations in 5 states (Colorado, Georgia, Kansas).
Frequently Asked Questions
What is clinical trial NCT06544265 about?
NCT06544265 is a clinical study titled "SynKIR-310 for Relapsed/Refractory B-NHL". This first-in-human (FIH) trial is designed to assess the safety, feasibility and preliminary efficacy of a single intravenous (IV) dose of SynKIR-310 administered to participants with relapsed/refractory B-NHL.
What is the current status of trial NCT06544265?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2024-11-01. Estimated completion is 2028-12.
What conditions does trial NCT06544265 study?
This clinical trial studies the following conditions: Mantle Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, B-cell Lymphoma, Refractory Non-Hodgkin Lymphoma.
What interventions are being tested in trial NCT06544265?
The interventions under investigation include: SynKIR-310 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06544265?
This trial is sponsored by Verismo Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06544265 being conducted?
This trial has 5 study locations across Colorado, Georgia, Kansas, New Jersey, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mantle Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06544265's enrollment target sits among peer trials
18 90th of 102 higher than 12 of 102 other Mantle Cell Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Mantle Cell Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
RECRUITING · Phase 1
-
A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma
RECRUITING · Phase 1
-
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
RECRUITING · Phase 1
-
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI